news
Cannabinoid screening reveals anti-tumour properties of CBC and CBG
A high-throughput screening test of different cannabinoids has demonstrated that CBC and CBG exhibit anti-tumour effects.
List view / Grid view
Screening
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
news
Could Frizzled receptors be the target of new cancer therapeutics?
The G-protein coupled receptor Frizzled, implicated in diseases like cancer, can be targeted with small molecules which could provide the basis for anti-cancer therapeutics, according to researchers.
news
Dozens of anti-cancer compounds revealed by screening existing drugs
Researchers have screened thousands of existing drug molecules against cancer cell lines to discover almost 50 compounds that combat the condition.
news
Metal-based fragment molecule library to screen for drug candidates
Researchers have developed a novel metal-based fragment library of molecules that can be used to screen for new drug candidates.
news
Industry collaborate to screen existing drugs to repurpose for cystic fibrosis
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
news
Genes associated with heavy alcohol use may also impact compulsive behaviour and addiction
A study suggests there may be common genetic pathways between alcohol use disorder and other addictions, so GWAS identification of affected genes could provide the targets for new therapies.
news
Screening platform reveals compounds that protect neuronal mitochondria
Researchers have developed a screening system and identified a set of compounds that protect neuronal mitochondria in mice.
whitepaper
ebook: The ELISA Guide – to your successful experiments
Enzyme Linked Immunosorbent Assays (ELISAs) are one of the most common immunoassays on the market.
news
Organoid models for personalised treatments of glioblastomas developed
Lab-grown brain organoids from patients’ glioblastomas could be useful models to rapidly test and identify effective personalised treatments, find researchers.
article
Exploring chemical space for epigenetic drug discovery using AI
It is said that, on average, it takes a new drug 12 years to go from research lab to patient, with many thousands of candidates discarded along the way. Can artificial intelligence (AI) help to speed things up? Sheraz Gul and Alp Sahin provide an overview of an AI approach…
news
Assay for reading six molecular pathways simultaneously developed
Researchers have developed a luciferase assay that can be used to monitor the effects of treatments on six different molecular targets at once.
article
Transitioning novel peptide hits into lead compounds
Unlike synthetic compound libraries, natural product hits must be identified and characterised, as the molecule is often unknown. Venom peptides are often inherently stable due to cysteine knots whereas other peptides may not be. Steve and Carol Trim discuss the challenges of the hit-to-lead journey with these non-standard hits.
article
CRISPR: kick-starting the revolution in drug discovery
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of…
article
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
article
Expert view – The Octet HTX system: enabling multi-purpose screening of therapeutic biologics during development
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
